Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jun 2021
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Rhodes Pharmaceuticals
- 14 Jun 2021 Results presented in the Adlon Therapeutics Media Release
- 31 May 2021 Results of post-hoc analyses based on a randomized, double-blind, forced-dose, placebo-controlled trial (NCT02139124) and an open-label extension study (NCT02168127) of the efficacy and safety of the extended-release methylphenidate hydrochloride formulation PRC-063 in adults with ADHD published in the CNS Drugs
- 16 Jan 2020 Results published in Adlon Therapeutics L.P.and Purdue Pharma Media Release